

THE AMENDMENTS

In the Specification

Amend the paragraph starting at page 6, line 4 with:

Figure 1 (SEQ ID NO:1) shows an embodiment of a nucleic acid (mRNA) which includes a sequence which encodes a differentially expressed protein provided herein, CHA4. Start (ATG) and stop (TAG) codons are underlined.

Amend the paragraph starting at page 6, line 7 with:

Figure 2 (SEQ ID NO:2) shows an embodiment of the amino acid sequence of CHA4.

Amend the paragraph starting at page 7, line 28 with:

In a preferred embodiment, the differentially expressed sequences are those of nucleic acids encoding CHA4 or fragments thereof. Preferably, the differentially expressed sequence is that depicted in figure 1 (SEQ ID NO:1), or a fragment thereof. Preferably, the differentially expressed sequences encode a protein having the amino acid sequence depicted in figure 2 (SEQ ID NO:2), or a fragment thereof. In a preferred embodiment, CHA4 is human Ephrin-A3.

Amend the paragraph starting at page 15, line 4 with:

In a preferred embodiment, the sequences which are used to determine sequence identity or similarity are selected from the sequences set forth in the figures, preferably those shown in Figures 1 and 2 (SEQ ID NOS:1 and 2, respectively) and fragments thereof. In one embodiment the sequences utilized herein are those set forth in the figures. In another embodiment, the sequences are naturally occurring allelic variants of the sequences set forth in the figures. In another embodiment, the sequences are sequence variants as further described herein.

Amend the paragraph starting at page 15, line 31 with:

Thus, "percent (%) nucleic acid sequence identity" is defined as the percentage of nucleotide residues in a candidate sequence that are identical with the nucleotide residues of figure 1 (SEQ

ID NO:1). A preferred method utilizes the BLASTN module of WU-BLAST-2 set to the default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively.

Amend the paragraph starting at page 46, line 25 with:

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as “differentially expressed proteins” or “cancer modulating proteins”. Additionally, “modulator” and “modulating” proteins are sometimes used interchangeably herein. In one embodiment, the differentially expressed protein is termed CHA4. CHA4 sequences can be identified as described herein for differentially expressed sequences. In one embodiment, CHA4 sequences are depicted in Figures 1 and 2 (SEQ ID NOS: 1 and 2, respectively). The differentially expressed protein may be a fragment, or alternatively, be the full length protein to the fragment shown herein. Preferably, the differentially expressed protein is a fragment. In a preferred embodiment, the amino acid sequence which is used to determine sequence identity or similarity is that depicted in figure 2 (SEQ ID NO:2). In another embodiment, the sequences are naturally occurring allelic variants of a protein having the sequence depicted in figure 2 (SEQ ID NO:2). In another embodiment, the sequences are sequence variants as further described herein.

In the Drawings

Please replace original Figures 3A-3D with the substitute sheets provided herein.